Cite
Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis.
MLA
Brown, Mark T., et al. “Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis.” Clinical Drug Investigation, vol. 43, no. 7, July 2023, pp. 551–63. EBSCOhost, https://doi.org/10.1007/s40261-023-01286-3.
APA
Brown, M. T., Cornblath, D. R., Koltzenburg, M., Gorson, K. C., Hickman, A., Pixton, G. C., Gaitonde, P., Viktrup, L., & West, C. R. (2023). Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis. Clinical Drug Investigation, 43(7), 551–563. https://doi.org/10.1007/s40261-023-01286-3
Chicago
Brown, Mark T, David R Cornblath, Martin Koltzenburg, Kenneth C Gorson, Anne Hickman, Glenn C Pixton, Puneet Gaitonde, Lars Viktrup, and Christine R West. 2023. “Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis.” Clinical Drug Investigation 43 (7): 551–63. doi:10.1007/s40261-023-01286-3.